FUCHS, C.S., K. MURO, Jiří TOMÁŠEK, E. VAN CUTSEM, J.Y. CHO, S.C. OH, H. SAFRAN, G. BODOKY, I. CHAU, Y. SHIMADA, S.E. AL-BATRAN, R. PASSALACQUA, A. OHTSU, M. EMIG, D. FERRY, K. CHANDRAWANSA, Y. HSU, A. SASHEGYI, A.M. LIEPA and H. WILKE. Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. JOURNAL OF GASTRIC CANCER. SEOUL: KOREAN GASTRIC CANCER ASSOC, 2017, vol. 17, No 2, p. 132-144. ISSN 2093-582X. Available from: https://dx.doi.org/10.5230/jgc.2017.17.e16.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
Authors FUCHS, C.S. (840 United States of America), K. MURO (392 Japan), Jiří TOMÁŠEK (203 Czech Republic, guarantor, belonging to the institution), E. VAN CUTSEM (56 Belgium), J.Y. CHO (410 Republic of Korea), S.C. OH (410 Republic of Korea), H. SAFRAN (840 United States of America), G. BODOKY (348 Hungary), I. CHAU (826 United Kingdom of Great Britain and Northern Ireland), Y. SHIMADA (392 Japan), S.E. AL-BATRAN (276 Germany), R. PASSALACQUA (380 Italy), A. OHTSU (392 Japan), M. EMIG (276 Germany), D. FERRY (840 United States of America), K. CHANDRAWANSA (840 United States of America), Y. HSU (840 United States of America), A. SASHEGYI (840 United States of America), A.M. LIEPA (840 United States of America) and H. WILKE (276 Germany).
Edition JOURNAL OF GASTRIC CANCER, SEOUL, KOREAN GASTRIC CANCER ASSOC, 2017, 2093-582X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Republic of Korea
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.400
RIV identification code RIV/00216224:14110/17:00099924
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.5230/jgc.2017.17.e16
UT WoS 000413196500004
Keywords in English Prognosis; Stomach neoplasms; Gastroesophageal junction; Survival
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 22/3/2018 17:32.
Abstract
Purpose: To identify baseline prognostic factors for survival in patients with disease progression, during or after chemotherapy for the treatment of advanced gastric or gastroesophageal junction (GEJ) cancer. Materials and Methods: We pooled data from patients randomized between 2009 and 2012 in 2 phase III, global double-blind studies of ramucirumab for the treatment of advanced gastric or GEJ adenocarcinoma following disease progression on first-line platinum-and/or fluoropyrimidine-containing therapy (REGARD and RAINBOW). Forty-one key baseline clinical and laboratory factors common in both studies were examined. Model building started with covariate screening using univariate Cox models (significance level=0.05). A stepwise multivariable Cox model identified the final prognostic factors (entry+exit significance level=0.01). Cox models were stratified by treatment and geographic region. The process was repeated to identify baseline prognostic quality of life (QoL) parameters. Results: Of 1,020 randomized patients, 953 (93%) patients without any missing covariates were included in the analysis. We identified 12 independent prognostic factors of poor survival: 1) peritoneal metastases; 2) Eastern Cooperative Oncology Group (ECOG) performance score 1; 3) the presence of a primary tumor; 4) time to progression since prior therapy <6 months; 5) poor/unknown tumor differentiation; abnormally low blood levels of 6) albumin, 7) sodium, and/or 8) lymphocytes; and abnormally high blood levels of 9) neutrophils, 10) aspartate aminotransferase (AST), 11) alkaline phosphatase (ALP), and/or 12) lactate dehydrogenase (LDH). Factors were used to devise a 4-tier prognostic index (median overall survival [OS] by risk [months]: high=3.4, moderate=6.4, medium=9.9, and low=14.5; Harrell's C-index=0.66; 95% confidence interval [CI], 0.64-0.68). Addition of QoL to the model identified patient-reported appetite loss as an independent prognostic factor. Conclusions: The identified prognostic factors and the reported prognostic index may help clinical decision-making, patient stratification, and planning of future clinical studies.
PrintDisplayed: 25/4/2024 23:06